Free Trial

Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics logo
$28.55 -0.28 (-0.98%)
Closing price 03:59 PM Eastern
Extended Trading
$28.60 +0.06 (+0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CLDX vs. PRAX, KRYS, PTGX, ABVX, and RYTM

Should you buy Celldex Therapeutics stock or one of its competitors? Celldex Therapeutics's main competitors and comparable companies include Praxis Precision Medicines (PRAX), Krystal Biotech (KRYS), Protagonist Therapeutics (PTGX), Abivax (ABVX), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Praxis Precision Medicines?

Celldex Therapeutics (NASDAQ:CLDX) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Praxis Precision Medicines' return on equity of -29.41% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
Praxis Precision Medicines N/A -29.41%-28.19%

Celldex Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A
Praxis Precision MedicinesN/AN/A-$303.27M-$12.80N/A

In the previous week, Praxis Precision Medicines had 18 more articles in the media than Celldex Therapeutics. MarketBeat recorded 33 mentions for Praxis Precision Medicines and 15 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.92 beat Praxis Precision Medicines' score of 0.63 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Praxis Precision Medicines
7 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Celldex Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Celldex Therapeutics currently has a consensus target price of $64.08, indicating a potential upside of 122.28%. Praxis Precision Medicines has a consensus target price of $631.68, indicating a potential upside of 92.51%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.91

Summary

Praxis Precision Medicines beats Celldex Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Celldex Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Krystal Biotech has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$389.13M23.24$204.83M$7.3741.42
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Celldex Therapeutics had 12 more articles in the media than Krystal Biotech. MarketBeat recorded 15 mentions for Celldex Therapeutics and 3 mentions for Krystal Biotech. Celldex Therapeutics' average media sentiment score of 0.92 beat Krystal Biotech's score of 0.89 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech presently has a consensus target price of $375.00, suggesting a potential upside of 22.86%. Celldex Therapeutics has a consensus target price of $64.08, suggesting a potential upside of 122.28%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Krystal Biotech has a net margin of 47.91% compared to Celldex Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 17.02% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech47.91% 17.02% 15.48%
Celldex Therapeutics N/A -52.66%-47.58%

Summary

Krystal Biotech beats Celldex Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Protagonist Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Celldex Therapeutics presently has a consensus price target of $64.08, indicating a potential upside of 122.28%. Protagonist Therapeutics has a consensus price target of $166.67, indicating a potential upside of 27.28%. Given Celldex Therapeutics' higher possible upside, equities analysts plainly believe Celldex Therapeutics is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06

Protagonist Therapeutics has a net margin of 62.04% compared to Celldex Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 42.83% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
Protagonist Therapeutics 62.04%42.83%40.29%

Celldex Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for Protagonist Therapeutics and 15 mentions for Celldex Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.97 beat Celldex Therapeutics' score of 0.92 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Protagonist Therapeutics beats Celldex Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Abivax?

Celldex Therapeutics (NASDAQ:CLDX) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Celldex Therapeutics presently has a consensus price target of $64.08, indicating a potential upside of 122.28%. Abivax has a consensus price target of $155.00, indicating a potential upside of 76.98%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Celldex Therapeutics' return on equity of -52.66% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
Abivax N/A -91.69%-71.96%

Celldex Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Abivax has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Celldex Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A
AbivaxN/AN/A-$380.27M-$6.06N/A

In the previous week, Celldex Therapeutics had 10 more articles in the media than Abivax. MarketBeat recorded 15 mentions for Celldex Therapeutics and 5 mentions for Abivax. Abivax's average media sentiment score of 1.13 beat Celldex Therapeutics' score of 0.92 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abivax
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Celldex Therapeutics beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Celldex Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Rhythm Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Celldex Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -69.03%. Celldex Therapeutics' return on equity of -52.66% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-69.03% -171.16% -43.00%
Celldex Therapeutics N/A -52.66%-47.58%

Rhythm Pharmaceuticals currently has a consensus price target of $142.00, indicating a potential upside of 23.46%. Celldex Therapeutics has a consensus price target of $64.08, indicating a potential upside of 122.28%. Given Celldex Therapeutics' higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Rhythm Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M42.02-$196.54M-$2.90N/A
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A

In the previous week, Celldex Therapeutics had 7 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 15 mentions for Celldex Therapeutics and 8 mentions for Rhythm Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.92 beat Rhythm Pharmaceuticals' score of 0.66 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Rhythm Pharmaceuticals and Celldex Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLDX vs. The Competition

MetricCelldex TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.24B$4.06B$7.83B$11.76B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-6.6424.2134.3230.12
Price / Sales14,194.8614.858.005.33
Price / CashN/A21.8921.0222.32
Price / Book3.604.354.763.85
Net Income-$258.76M-$24.19M$3.52B$391.27M
7 Day Performance-8.62%-7.23%-5.35%-4.55%
1 Month Performance3.70%-4.94%-3.62%-5.89%
1 Year Performance11.73%-4.60%-0.62%-7.84%

Celldex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLDX
Celldex Therapeutics
2.0895 of 5 stars
$28.55
-1.0%
$64.08
+124.5%
+12.8%$2.24B$158KN/A198
PRAX
Praxis Precision Medicines
2.9352 of 5 stars
$333.08
+0.0%
$630.42
+89.3%
+76.0%$9.34B$8.55MN/A168
KRYS
Krystal Biotech
3.7465 of 5 stars
$303.54
+0.2%
$375.00
+23.5%
+48.1%$8.99B$389.13M41.19295
PTGX
Protagonist Therapeutics
3.5254 of 5 stars
$137.08
+3.8%
$166.67
+21.6%
+54.8%$8.86B$46.02M29.00141
ABVX
Abivax
3.3119 of 5 stars
$89.84
+3.3%
$155.00
+72.5%
-20.7%$7.84BN/AN/A98

Related Companies and Tools


This page (NASDAQ:CLDX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners